Is NCT06792825 recruiting in Minneapolis, MN?

Yes, NCT06792825 is currently recruiting participants at its Minneapolis, MN location. This follicular lymphoma clinical trial is actively enrolling qualified participants.

How do I join the follicular lymphoma clinical trial in Minneapolis?

To join this clinical trial in Minneapolis, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Minneapolis clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Follicular Lymphoma Clinical Trial in Minneapolis, MN

About This Follicular Lymphoma Study in Minneapolis

The study follows a Simon's two-stage phase II trial design to evaluate the safety and efficacy of tafasitamab added to rituximab and lenalidomide for two treatment-naïve, parallel, independent cohorts: follicular lymphoma (FL) and marginal zone lymphoma (MZ). Each cohort, FL and MZ, will be evaluated separately. This study is presented to the patient and consent is signed prior to the initiation of treatment for their primary malignancy.

Sponsor: Masonic Cancer Center, University of Minnesota

Who Can Participate

Inclusion Criteria

Histologically confirmed marginal zone lymphoma

Histologically confirmed CD20+ follicular lymphoma stage 1, 2 or 3a

No prior systemic therapy for lymphoma

Must be in need of treatment as evidenced by one or more of the following criteria:

Bulky disease defined as:

a nodal or extranodal (except spleen) mass \>7cm in its greater diameter or,

involvement of at least 3 nodal or extranodal sites (each with a diameter greater than \>3 cm)

Presence of at least one of the following B symptoms:

fever (\>38C) of unclear etiology

night sweats

weight loss greater than 10% within the prior 6 months

Any other symptoms attributable to lymphomatous mass

Endangerment of vital organ due to lymphomatous mass including but not limited to:

Symptomatic or massive splenomegaly

Compression syndrome (including but not limited to ureteral, orbital, gastrointestinal)

Pleural, pericardial or ascitic effusion regardless of cell count

Follicular lymphoma in leukemic phase (\>5 X 109/L circulating cells) OR:

Follicular lymphoma graded high-risk by FLIPI2 score (see Appendix III)

Adequate organ function within 14 days (28 days for pulmonary or cardiac) of study registration

Participants who are of childbearing potential or have partners of child-bearing potential must agree to either total abstinence or use of both a highly effective (IUD, hormonal contraceptives, tubal ligation or vasectomy), and effective contraception (male or female condom, diaphragm or cervical cap) for the duration of treatment and for 12 months after the last dose of study drug.

Able to tolerate prophylactic anticoagulation/antiplatelet therapy while on lenalidomide

Able to provide written voluntary consent prior to the performance of any research related tests or procedures (or the subject's legally authorized representative (LAR) if enrollment of persons with diminished capacity is permitted - general permitted for Phase II and greater studies)

Exclusion Criteria

Seropositive for or active viral infection with hepatitis B virus (HBV):

HBV surface antigen (HBsAg) positive

HBV surface antigen (HBsAg) negative, HBV surface antibody (anti-HBs) positive and/or HBV core antibody (anti-HBc) positive, and detectable viral DNA

Hepatitis C virus (HCV) positive subjects with chronic hepatitis C, or subjects with an active hepatitis C infection requiring anti-viral medication (at time of randomization).

Known seropositive for or active viral infection with human immunodeficiency virus (HIV).

Prior history of lenalidomide use

Prior history of malignancies, other than follicular or marginal zone lymphoma, unless the subject has been free of the disease for ≥ 5 years.

Peripheral neuropathy ≥ grade 2 at time of screening

Uncontrolled intercurrent illness.

Active infection (requiring systemic therapy) or has received a live vaccine within 14 days prior to first dose of study drug.

Presence or history of CNS involvement by lymphoma

Patients who are not willing to take venous thromboembolic (VTE) prophylaxis or antiplatelet therapy

Recent ( \<1 year ) arterial thrombosis (any) or venous thrombosis ≥ grade 3 by CTCAE 5.0.

Pregnant or breastfeeding as agents used in this study are Pregnancy Category X. Women of childbearing potential must have two negative pregnancy tests (serum or urine) prior to their first dose of lenalidomide, and must agree to scheduled pregnancy testing while on treatment regardless of their birth control choice, per the requirements of the lenalidomide risk evaluation and mitigation strategy (REMS) program.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Minneapolis?

Yes, this clinical trial (NCT06792825) has an active research site in Minneapolis, MN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Follicular Lymphoma Treatment Options in Minneapolis, MN

If you're searching for follicular lymphoma treatment options in Minneapolis, MN, this clinical trial (NCT06792825) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Minneapolis research site is actively enrolling participants for this clinical trial. You'll receive care from experienced follicular lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all follicular lymphoma clinical trials near you to find additional studies recruiting in your area.

Follicular Lymphoma Clinical Trial in Minneapolis, MN

Expert Care in Minneapolis

IRB Approved

No-Cost Care

Apply for This Minneapolis Location

Why Participate?

Simple Process